Xenon Pharmaceuticals Inc. (XENE) Stock
8 of the hedge funds AlphaScala tracks reported XENE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $84.58M. Company insiders reported 2 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own XENE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.40M | $84.58M | -47% |
| Marshall Wace | 689K | $41.61M | NEW |
| Millennium Management Israel Englander | 377K | $22.74M | +87% |
| Duquesne Family Office Stanley Druckenmiller | 239K | $14.40M | n/a |
| D.E. Shaw David Shaw | 224K | $13.52M | +1082% |
| Renaissance Technologies Jim Simons (founder) | 187K | $11.29M | -38% |
| Point72 Steve Cohen | 130K | $7.87M | NEW |
| Blackstone | 8K | $459.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Xenon Pharmaceuticals Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Mortimer Ian | PRESIDENT & CEO | BUY | 30.0K | $1.1M |
| Sep 30, 26 | Kelly Thomas Patrick | Chief Financial Officer | BUY | 15.0K | $560K |
| Aug 28, 26 | Kenney Christopher John | Chief Medical Officer | SELL | 6.4K | $383K |
| Aug 28, 26 | Kenney Christopher John | Chief Medical Officer | SELL | 700 | $43K |
| Aug 11, 26 | Gannon Steven | Director | SELL | 10.0K | $641K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →XENE price chart
Powered by TradingViewWhat does Xenon Pharmaceuticals Inc. do?
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders. The company's lead molecule, azetukalner, is a novel potent selective Kv7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression. Xenon's pipeline also includes early-stage potassium and sodium channel modulators, with Kv7 and Nav1.7 programs in Phase 1 development for pain management. The company addresses areas of high unmet medical need in rare central nervous system conditions and other neurological disorders. Headquartered in Burnaby, British Columbia, with additional offices in Boston, Massachusetts, Xenon operates as a clinical-stage biopharmaceutical company committed to improving the lives of patients living with complex neurological conditions.